Board summary
Key figures
44,151
Registered population
59.2% aged 18–64
20.5%
Aged 65+
ICB 15.7% · England 17.9%
7.2%
Ethnic minority (non-White)
3.8% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 3.0% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,317
Hypertension register
+6.62% in 3 yrs · England +5.60%
359
SMI register
27.3% of Waverley's
588
COPD register
Reviews +9.87% in 3 yrs
Forecast to 2030
7,183
Hypertension patients, 2030
+866 on today
68.8%
QRISK ≥20% on statins, 2030
+3.31pp over 3 yrs
5.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-eighty blood pressure control lags ICB and England.
Control under 80 is 66.5%, below England (67.8%) and the ICB (69.6%), despite 91.9% recent blood pressure recording and 83.2% control at 80+.
Wide practice variation in phone access and vaccinations.
Phone access spans 26.2 pp (37.5% at Farnham Park Health Group to 63.6% at Central Surgery) and QOF vaccination achievement spans 31.3 pp.
Heart failure and SMI checks ahead of England.
Heart failure reviews rose +42.1% over 2023 to 2025 (England +8.7%), and SMI blood pressure checks reach 87.9% against 83.4% in England.
Population, age and ethnicity
Patients aged 65+ comprise 20.5% of the list alongside 20 care homes
Farnham PCN serves 44,151 registered patients across three practices. Patients aged 65+ make up 20.5% of the list (9,039 patients), below Waverley (22.0%) but above NHS Frimley Integrated Care Board (15.7%) and England (17.9%). Resident Census estimates—measuring local usual residents rather than registered patients—record 92.8% White ethnicity (Waverley 93.6%, ICB 74.1%, England 81.1%) and 3.8% Asian / Asian British (Waverley 2.8%, ICB 17.3%, England 9.6%). Projected population growth to 2030 is 0.7% under an unverified ONS methodology, trailing Waverley (3.0%), NHS Frimley Integrated Care Board (2.5%), and England (2.3%).
Age profile
65+: ICB 15.7%, England 17.9%
Ethnicity
Older people · falls rows are Waverley local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Waverley LA) | 2,164 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 87.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Waverley LA) | 912 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Waverley LA) | 9.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.6 with 0.0% in Core20 across all three practices
Farnham PCN has an average IMD decile of 8.6, compared to 8.5 in Waverley, 7.5 in NHS Frimley Integrated Care Board, and 5.5 in England. Across all 3 practices—Central Surgery (8.8), Farnham Dene Medical Practice (8.7), and Farnham Park Health Group (8.7)—0.0% of registered patients live in Core20 areas (0 estimated patients), matching Waverley (0.0%) and below NHS Frimley Integrated Care Board (3.0%) and England (21.0%). This suggests inequality initiatives may need to target individual clinical inclusion rather than area-level deprivation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
359
SMI register
0.80% recorded prevalence
219
Learning disability register
0.49% recorded prevalence
20
Care homes, 818 beds
In the PCN catchment
7.8%
Provide unpaid care
Waverley, Census 2021
The catchment includes 20 care homes with 818 beds, alongside registers of 417 dementia patients (0.9%), 359 severe mental illness patients (0.8%), and 219 with learning disabilities (0.5%). Care home bed capacity does not confirm resident patient occupancy. Crude prevalence does not establish unmet need, but higher dementia prevalence than England (0.8%) could warrant coordinated care home reviews.
Severe mental illness: physical health checks
Across 359 severe mental illness patients, 12-month checks reached 87.9% for blood pressure and 88.3% for BMI (England 83.4% and 82.1%). However, BMI recording was 76.9% at Farnham Dene Medical Practice.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,317
Hypertension register
+6.62%
Register growth, 3 yrs
Waverley +6.01% · England +5.60%
+4.19pp
BP control, under 80
≤140/90 · +3.69pp aged 80+
+866
More patients by 2030
Forecast 7,183 (15.91%)
Hypertension case-finding and control
Recent blood pressure recording reached 91.9% across 6,317 hypertension patients (England 90.0%, NHS Frimley ICB 90.1%, Waverley 89.7%). Control in patients aged 80+ reached 83.2% (England 81.2%). For patients aged under 80, control was 66.5% (England 67.8%, ICB 69.6%), spanning 61.5% at Farnham Dene Medical Practice, 65.8% at Farnham Park Health Group, and 71.9% at Central Surgery. Crude hypertension prevalence was 14.0% (England 15.2%). Under-80 blood pressure control trails regional benchmarks, which may indicate unaddressed review or titration opportunities.
Lipids and statins
Lipid-lowering therapy reached 61.6% of patients with QRISK ≥ 20% (England 63.6%, NHS Frimley ICB 64.7%) and 66.2% of CKD patients (England 70.3%, NHS Frimley ICB 71.4%). Statin treatment for patients with diabetes aged 40+ without cardiovascular disease reached 76.0% (England 73.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 56,124 | £2.50 | £2.23 | £1.86 | £140,310 |
| Cardiovascular (all), 2025 | 81,162 | £4.72 | £4.03 | £3.33 | £383,085 |
For lipid-regulating drugs in 2026, the PCN prescribed 56,124 items at £2.50 per item (Waverley £2.12, NHS Frimley ICB £2.23, England £1.86). Across these 56,124 items, the PCN spent £35,919 more than at England's unit cost. Unit cost reflects prescribing choices rather than overall efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.22%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.44%
Asthma prevalence, PCN 3-yr % change
COPD prevalence was 1.3% (588 patients; England 1.9%), falling 1.8% over 2023 to 2025 (England +2.6%), while reviews reached 83.5% (England 76.4%). On the 2,607-patient asthma register (6.1% prevalence; England 6.6%), 12-month reviews reached 70.9% (England 65.7%) but fell 0.2% over 2023 to 2025 (England +4.4%), leaving about 760 patients unreviewed. Youth asthma prescribing was 589 items per 1,000 population aged 5 to 19 (England 1,488).
Cancer register and children's immunisation
Cancer register prevalence is 4.7% (2,102 patients; England 3.8%). In childhood immunisations, complete 6-in-1 coverage at 24 months reaches 96.8% (England 92.2%), exceeding the 95.0% target. However, age-5 MMR2 coverage is 89.1% (England 82.8%), trailing the 95.0% standard. At Farnham Park Health Group, MMR coverage drops 4.9 pp between first (82.9%) and second dose (78.0%), leaving children vulnerable to incomplete protection.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
57.3%
Frimley ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~500
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Frimley ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.3% | 85.4% | 21% | 537 |
| Prostate | 52.0% | 53.2% | 22% | 440 |
| Bowel | 50.2% | 47.0% | 17% | 406 |
| Lung | 33.3% | 33.8% | 16% | 324 |
| Skin cancer | 84.4% | 87.8% | 17% | 225 |
In 2022, NHS Frimley ICB diagnosed 57.3% of cancers at stage 1 or 2 across all sites (1,622 of 2,830 cancers with a known stage), above England's 55.3% but 17.7 pp below the 75.0% national ambition by 2028. Closing this ICB gap would require about 500 extra early-stage cases (500.5). Known-stage coverage was 67.8% (2,830 of 4,174 registered cancers; England 67.0%). Bowel cancer early diagnosis stood at 50.2% (England 47.0%), 24.8 pp below target. In small cohorts, like oesophagus (8 of 71 staged, 11.3%), low numbers limit interpretation. These data reflect wider system pathways rather than PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Frimley Health NHS Foundation Trust achieved 87.9% on the 28-day faster diagnosis standard (12.9 pp above the 75.0% standard), ahead of Royal Surrey NHS Foundation Trust (82.6%), Hampshire Hospitals NHS Foundation Trust (78.8%), NHS Surrey and Sussex Integrated Care Board (79.3%), and England (79.3%). On the 62-day standard, Frimley Health reached 81.8% (3.2 pp below the 85.0% standard), against 84.5% at Royal Surrey NHS Foundation Trust, 71.8% at Hampshire Hospitals NHS Foundation Trust, 71.5% in NHS Surrey and Sussex Integrated Care Board, and 71.2% nationally.
| Pathways within standard (%) | Frimley Health | Royal Surrey | Hampshire | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 87.95 | 82.62 | 78.84 | 79.29 | 79.32 |
| 31-day treatment (96%) | 92.89 | 96.43 | 91.99 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 81.84 | 84.48 | 71.78 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Frimley Health | Royal Surrey | Hampshire | England |
|---|---|---|---|---|
| MRI | 12.85 | 0.00 | 12.16 | 21.40 |
| CT | 0.63 | 0.15 | 2.03 | 9.92 |
| Echocardiography | 3.35 | 1.55 | 2.16 | 28.48 |
| Colonoscopy | 22.84 | 0.00 | 72.77 | 30.83 |
| Gastroscopy | 7.43 | 0.00 | 75.15 | 29.02 |
| All 15 DM01 tests | 7.49 | 8.82 | 23.87 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In June 2026 (provisional), 109,530 community care contacts were recorded for Surrey residents, with adults aged 65+ accounting for 69.6% of contacts (76,215). These experimental data cover submitting providers across the local authority rather than PCN-level activity, describing wider system contacts rather than Farnham PCN patients.
Practice variation and patient experience
Phone access varies by 26.2 pp across practices alongside divergence in vaccination achievement
QOF overall achievement in 2025/26 reached 98.5% at Farnham Dene Medical Practice, 97.2% at Central Surgery, and 95.1% at Farnham Park Health Group (England 92.5%). However, vaccination and immunisation achievement diverged by 31.3 pp, from 89.6% at Farnham Dene Medical Practice to 58.4% at Farnham Park Health Group (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Central Surgery | 127 | 0.0 | 63.6% | 74.3% | 76.2% |
| Farnham Dene | 110 | 0.0 | 47.3% | 67.4% | 66.5% |
| Farnham Park | 94 | 0.0 | 37.5% | 66.9% | 61.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Heart failure reviews improved sharply while four measures lagged three-year national trends
Over 2023 to 2025, heart failure reviews grew 42.1% (England +8.7%), reaching 79.4%, and statin therapy in diabetes without cardiovascular disease rose 12.7% (England +2.1%). Conversely, four indicators lagged national three-year trends: asthma reviews fell 0.2% (England +4.4%), the recorded COPD register declined 1.8% (England +2.6%), breast screening rose 5.8% over 2023 to 2024 (England +8.4%), and QRISK ≥ 20% lipid therapy rose 5.7% (England +6.2%). Local clinical audit would test whether trailing reviews reflect unrecorded recall needs.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
COPD register
Breast screening (53-70)
QRISK statin treatment
Heart failure reviews
Diabetes statin (no CVD)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Waverley | Asset | PCN | Waverley |
|---|---|---|---|---|---|
| Care homes (catchment) | 20 (818 beds) | n/a | Schools (catchment) | 51 | n/a |
| Children's centres | 3 | 7 | Places of worship | 39 | 95 |
| Libraries | 1 | 4 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 2 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 9 | 18 |
| Primary academies | 6 | 17 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Under-eighty blood pressure titration recall
Under-80 hypertension BP control is 66.5% (Waverley 65.3%, ICB 69.6%, England 67.8%), spanning 61.5% at Farnham Dene Medical Practice to 71.9% at Central Surgery. For discussion: the PCN could run pharmacist-led medication titration and remote monitoring recall for patients aged under 80 above target. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured annual asthma review recall
On the 2,607 asthma register, 70.9% had a 12-month review (England 65.7%), but reviews fell 0.2% over 2023 to 2025 (Waverley +6.2%, ICB +4.6%, England +4.4%), leaving 759 (about 760) unreviewed. For discussion: practices could standardise annual asthma review templates and offer flexible or remote slots with inhaler checks. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Stroke register coding and case-finding
Recorded stroke prevalence is 1.7% (780 patients across 44,151 registered), below Waverley (1.9%) and England (1.9%) and above ICB (1.5%), giving a crude benchmark gap of 54 to 59 patients. For discussion: practices could run an electronic health record search for historical stroke or TIA codes missing from QOF registers. Low cost, quick to run.
Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.
Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Proactive older age care review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Target clinical and inclusion vulnerability (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Targeted SMI physical health checks (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | Practice |
| Under-eighty blood pressure titration review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR second dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Earlier cancer referral and presentation review (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Telephony and access process review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Under-eighty blood pressure titration recall (p12) | Hypertension register · Hypertension patients with a recent BP reading · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Stroke register coding and case-finding (p12) | Stroke register · Stroke: QOF prevalence · Registered population | Core20PLUS5 CVD · CVDPREVENT · SSNAP | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
